Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back

Safety Profile Will Be Battleground

Executive Summary

AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.

You may also be interested in...



AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results

The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.

GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back

While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel